Practice Areas & Industries: Duane Morris LLP

 




Antitrust Clearance and Compliance Return to Practice Areas & Industries

Group Profile Lawyers in this Group Offices Locations for this Group
 

Practice/Industry Group Overview

Antitrust laws affect almost every company that does business in the United States, regulating relations with their markets, competitors, suppliers and customers. These laws are serious. Violations trigger serious consequences.

Duane Morris' corporate antitrust practice can help companies with essential guidance on antitrust counseling, M&A transactions and merger clearance, and antitrust training and audits.

Antitrust Counseling

Antitrust law's reach extends to most companies doing business in the United States, even those in so-called "exempt" industries, which are almost always governed by competition law through some agency regulation. Inadvertently violating antitrust law carries great risks from government or private action. Like many other areas of law, it is prudent to understand the law so you can plan your business operations to minimize risk.

Lawyers at Duane Morris regularly advise companies on all antitrust market-conduct issues, including:

  • pricing
  • price discrimination
  • product distribution
  • dealer terminations
  • standard setting
  • trade association activity
  • relationships with competitors
  • refusals to deal
  • information exchanges

Our attorneys work with clients' in-house lawyers and executives to create an economical program that fits the business' needs.

M&A Transactions and Merger Clearance

Duane Morris attorneys have counseled companies of all sizes, including Fortune 100 companies, on domestic and international merger clearance issues.

We have cleared extraordinarily complex and disputed mergers before the Department of Justice (DOJ) and Federal Trade Commission (FTC), well as in the European Union, and have supervised both U.S. and international antitrust clearances in 75 countries. We also provide integration planning and guidance. Our antitrust attorneys have worked in all sorts of industries, such as biotech; insurance; Internet; recorded music; and energy, including oil, gas, LNG, pipeline, coal, electric generation and electric transmission.

Planning the antitrust aspects of a merger starts as soon as the parties consider the project. Duane Morris lawyers can offer essential preliminary advice to get the deal started on the right path.

Antitrust Training and Audits

It is vital for businesses to have an antitrust policy, ensure that executives and employees are trained in antitrust compliance and periodically check that the policy and training are producing the right results. Our lawyers are experienced with helping companies set up an antitrust policy, and they can also provide essential training through in-house seminars for your legal staff and employees.

Of course, the best corporate antitrust policy is of no use if businesses do not comply with it. We help clients manage periodic audits to make sure employees respect and observe the antitrust policy.

Antitrust Litigation and Other Services

In addition, Duane Morris has litigators experienced in contentious antitrust matters, ranging from claims of price-fixing and attempted monopolization to grand jury investigations and class actions. The firm also has superior bench strength in intellectual property, bankruptcy, healthcare, employment law and many other disciplines.


 
 
Articles Authored by Lawyers at this office:

FDA's New Interpretation of the Five-Year NCE Exclusivity Provisions of Federal Food, Drug, and Cosmetic Act
, March 06, 2014
The U.S. Food and Drug Administration (FDA) recently published its response to three citizen petitions and its draft Guidance for Industry relating to the determination of the five-year new chemical entity (NCE) exclusivity for fixed-combination drugs.

FDA's Guidance for Industry Concerning Receipt Dates
, February 18, 2014
The U.S. Food and Drug Administration (FDA) on February 10, 2014, published its Guidance for Industry on the receipt date for regulatory submissions. The Guidance applies to submissions that are in electronic or paper format, including submissions that are a hybrid of both.

FDA Releases Draft Guidance on Bioequivalence Requirements for ANDA Applicants
, December 11, 2013
On December 4, 2013, the U.S. Food and Drug Administration (FDA) issued a draft guidance on demonstrating bioequivalence for drugs submitted under an Abbreviated New Drug Application (ANDA). Entitled Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA, the new...

Compounding Pharmacies Now Subject to Federal Oversight
, December 04, 2013
On November 27, 2013, President Obama signed into law the Drug Quality and Security Act. Title I of this law—entitled the Compounding Quality Act (the "CQA")—allows the federal Food and Drug Administration (FDA) to oversee drug compounding in human health. The CQA does not...

FDA Proposed Rule Would Require Generics to Update Label Warnings Even Before Branded Pharmaceuticals Do
, November 15, 2013
On Wednesday, November 13, 2013, the U.S. Food and Drug Administration (FDA) will publish a proposed rule in the Federal Register that will mandate that generic drug firms update their labels for drugs under approved Abbreviated New Drug Applications (ANDAs) to add warnings, precautions, adverse...

Mobile Medical Apps Guidance
, October 08, 2013
Mobile health ("mHealth") application ("app") developers, manufacturers, investors, healthcare providers and others received welcome news late last month when the U.S. Food and Drug Administration ("FDA") published its long-awaited final guidance on mobile medical...